NewsRoom Articles - Page 75 of 154 - PsychedelicNewsWire (PNW)

TuesdayDec 21, 2021 3:17 pm

Survey Finds That People Microdosed on Psychedelics to Cope with Pandemic

A recently conducted survey has discovered that during the coronavirus pandemic, individuals who use drugs recreationally have been microdosing on psychedelic substances to improve their mental health. Researchers believe that this discovery shows that some individuals living with mental health conditions obtained relief from microdosing on substances such as psilocybin mushrooms and LSD. The survey was conducted by the Global Drug Survey, an independent research company based in London. From December 2020 to March 2021, the company gathered data from more than 32,000 individuals in 20 countries. The survey found that the majority of the respondents who had used psychedelics…

MondayDec 20, 2021 3:42 pm

DEA in Favor of White House Proposal to Streamline Research on Schedule I Substances

The National Institute on Drug Abuse and the Drug Enforcement Administration (“DEA”) are supporting a new White House plan that would streamline the process of studying substances classified under Schedule I, including cannabis and psychedelics such as psilocybin and LSD. During a House Energy and Commerce subcommittee hearing held earlier this month, the agencies declared their support for the research proposal. The proposal, dubbed the Office of National Drug Control Policy research plan, would also address concerns in the scientific community, including the challenges researchers face when trying to study Schedule I substances. In its written testimony, the DEA stated…

MondayDec 20, 2021 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022 Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase value for its shareholders There has been a huge misunderstanding of the psychedelic space and the potential that this industry has, specifically regarding the treatment of Post-Traumatic Stress Disorder (“PTSD”) and smoking cessation.…

FridayDec 17, 2021 3:14 pm

Survey Finds That Parents are Open to Ketamine Treatment for Adolescents

A new survey has found that most parents are accepting of the use of ketamine therapy with adolescents to treat bipolar disorder, major depressive disorder and suicidal ideation. This first-of-its-kind study assessed the attitudes of parents toward the use of ketamine as a treatment for adolescent suicidality and mood disorders. Its findings were reported in the “Journal of Child and Adolescent Psychopharmacology.” In the report, the authors of the study stated that since parents had the capacity to make decisions for their child’s medical care, consent from parents was a crucial factor in adopting new treatments for them. Figures from…

FridayDec 17, 2021 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Announces Ketamine Wellness Centers Partnerships With Veterans Administration; Meet Delic Becomes World’s Largest Psychedelic Conference

Ketamine Wellness Centers (“KWC”) has partnered with the Veterans Administration (“VA”) Community Care Networks in Illinois and Minnesota KWC will provide veterans with ketamine treatments for depression, chronic pain and PTSD at no out-of-pocket cost at these locations Meet Delic was held on November 6 and 7 and became the world’s largest psychedelic wellness event Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has announced its subsidiary, Ketamine Wellness Centers LLC (“KWC”), has entered two new partnerships with the Veteran Administration (“VA”) Community Care Networks of Illinois and Minnesota. KWC, which…

ThursdayDec 16, 2021 1:53 pm

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) to Conduct Study Investigating Effect of Time on LSD Microdosing

Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers to consuming a small dose of a recreational dose of a psychedelic, the most commonly used substances being psilocybin and LSD. The biotech firm announced that its research would focus on assessing and comparing evening and daytime administration of microdoses of LSD. LSD is a psychedelic drug whose effects include intensified emotions, thoughts and sensory perception. For microdoses, small doses are…

WednesdayDec 15, 2021 3:02 pm

Study Opens Door for Future Clinical Trials on Psychedelics for Chronic Pain

Various studies have found that psychedelic substances may be used in the treatment of chronic pain, depression and anxiety, among other indications. Research by Imperial College London looked into the effects of self-medicating psychedelics for the management of chronic pain. While it didn’t evaluate the substances’ effectiveness in treating chronic pain, the study opens the door to different clinical trials that will be carried out in a couple of years. Chronic pain is defined as pain that lasts for more than three months. Estimates show that roughly 20% of the global population lives with chronic pain. Severe and debilitating chronic…

TuesdayDec 14, 2021 3:51 pm

Are Celebrities Helping or Hindering Psychedelics Reform Movement?

The psychedelic renaissance has greatly increased the popularity of psychedelic substances as more research on these substances reveals the numerous benefits they possess. For instance, research has found that psilocybin may be used in the treatment of anxiety while MDMA could be used to manage post-traumatic stress disorder. In the recent past, we have also seen celebrities such as Lil Nas X, Miley Cyrus, Megan Fox and Will Smith speak openly about the use of psychedelics and how the substances have assisted them in overcoming mental health issues. In addition, they revealed how the substances had improved their creative pursuits.…

TuesdayDec 14, 2021 12:37 pm

Meet Delic Sells Out, Becomes World’s Largest Psychedelic Conference

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) held the Meet Delic conference from November 6-7, 2021, in Las Vegas, Nevada The event drew over 2,500 attendees, becoming the largest psychedelic wellness and business conference in the world The event featured over 60 expert speakers and thought leaders, including former NBA champion Lamar Odom and comedian Duncan Trussell Organizers have announced new dates for Meet Delic 2022 in Las Vegas In 2015, famed NBA basketball star Lamar Odom was hospitalized in Las Vegas following a near-death overdose, which resulted in multiple seizures, strokes, and a coma. He would go on to…

MondayDec 13, 2021 2:00 pm

Compass Pathways (NASDAQ: CMPS) Announces Promising Data from Psilocybin Therapy Trial

Recently, Compass Pathways (NASDAQ: CMPS) released new data on its COMP360 psilocybin therapy, which highlights that there’s no evidence suggesting that psilocybin gives rise to serious adverse events. The data also shows that the treatment could provide benefits beyond decreasing depressive symptoms in patients with depression. The psychedelic company’s findings add to data released in November from its phase 2b clinical trial that tested the effectiveness of COMP360 in managing treatment-resistant depression. The trial, which is said to be the biggest psilocybin therapy trial carried out to date, compared two active doses of the therapy — 10 mg and 25 mg…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000